Firm aims to boost pharmaceutical and vaccine business by 5% annually for five years
GSK has cut its dividend and set ambitious sales targets as its under-pressure chief executive, Dame Emma Walmsley, pledged to lead Britain’s second-biggest drugmaker through a corporate shake-up next year.
GSK is spinning off its consumer healthcare business and aims to increase sales at the remaining pharmaceuticals and vaccines business, provisionally called “New GSK”, by 5% annually over the next five years, while profits are projected to grow by 10% a year.
